{
  "teamId": "15",
  "lang": "ZH",
  "region": "Japan",
  "project": "",
  "company": "PRISM BioLab",
  "contact": { "name": "Dai Takehara", "occupation": "President & CEO", "avatarUrl": "https://expo.taiwan-healthcare.org/data/cht/20241116/20241116wx1p0l.jpeg" },
  "logoUrl": "https://expo.taiwan-healthcare.org/data/cht/20241116/20241116vfl470.jpeg",
  "mainInvester": "DBJ Capital",
  "established": "2006",
  "fundingAmount": "$60M",
  "annualRevenue": "$2M",
  "currentFundingRound": "IPO round",
  "currentFundingAmount": "$14M",
  "postMoneyValuation": "On Market",
  "highlights": ["Number of Programs both internal and collaborations with global pharma."],
  "coreTech": "Small molecule platform enabling to target intracellular PPI.",
  "coreTechKeywords": ["Protein-Protein Interaction", "Small molecule", "Peptide mimetics"],
  "targetMarket": "Growth market",
  "coreProducts": [
    { "name": "E7386", "type": "drug", "progress": 0.7, "countries": "" },
    { "name": "PRI724", "type": "drug", "progress": 0.7, "countries": "" }
  ],
  "milestones": ["Traded at Tokyo Stock Exchange."]
}
